Previous close | 28.82 |
Open | 29.99 |
Bid | 29.45 x 100 |
Ask | 30.05 x 100 |
Day's range | 29.45 - 31.00 |
52-week range | 4.00 - 31.00 |
Volume | |
Avg. volume | 132,205 |
Market cap | 450.335M |
Beta (5Y monthly) | 2.18 |
PE ratio (TTM) | N/A |
EPS (TTM) | -61.80 |
Earnings date | 10 May 2024 - 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 68.33 |
REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU. The S
Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell